Yahoo · Oct 21, 2026
Sanofi and ScionxBio partner on mRNA therapies
ScionxBio will direct optimisation programmes through to in vivo validation.
SN
NASDAQ · SNY
Sanofi
Healthcare · Drug Manufacturers - General
$43.13
Up+$1.21 (+2.81%)
Updated Oct 31, 2026, 12:49 AM
SID Score
7.2/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 119.04B
- P/E ratio
- 11.2
- Dividend yield
- 5.13%
- 52-week range
- $39.07 – $52.68
- Volume
- 4.27M
- Avg. volume
- 2.95M
Price performance · SNY
SNY price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
SNY closed at $43.13 after 20 trading sessions, up 8.04% for the selected period.
- Last close
- $43.13
- Period change
- +8.04%
- Period low
- $39.12
- Period high
- $43.13
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $42.34 | $43.15 | $42.17 | $43.13 | 4.27M |
| Oct 28, 2026 | $41.83 | $42.33 | $41.63 | $42.24 | 2.91M |
| Oct 27, 2026 | $41.55 | $41.965 | $41.5324 | $41.89 | 2.45M |
| Oct 26, 2026 | $41.76 | $41.89 | $41.45 | $41.79 | 2.68M |
| Oct 23, 2026 | $41.70 | $41.75 | $41.33 | $41.60 | 2.01M |
| Oct 22, 2026 | $41.17 | $42.11 | $41.07 | $41.96 | 3.46M |
| Oct 21, 2026 | $41.20 | $41.54 | $40.84 | $40.97 | 3.11M |
| Oct 20, 2026 | $40.62 | $41.45 | $40.56 | $41.40 | 4.24M |
| Oct 19, 2026 | $39.84 | $40.11 | $39.505 | $39.57 | 3.62M |
| Oct 16, 2026 | $40.36 | $40.61 | $40.16 | $40.61 | 4.63M |
| Oct 15, 2026 | $40.64 | $40.87 | $40.17 | $40.29 | 5.05M |
| Oct 14, 2026 | $39.37 | $39.995 | $39.33 | $39.77 | 5.34M |
| Oct 13, 2026 | $40.12 | $40.12 | $39.07 | $39.12 | 3.99M |
| Oct 12, 2026 | $40.24 | $40.315 | $39.685 | $39.74 | 2.94M |
| Oct 9, 2026 | $40.17 | $40.305 | $39.92 | $40.07 | 2.1M |
| Oct 8, 2026 | $40.18 | $40.265 | $39.5848 | $40.23 | 3M |
| Oct 7, 2026 | $39.94 | $40.25 | $39.72 | $40.20 | 2.08M |
| Oct 6, 2026 | $40.05 | $40.05 | $39.235 | $39.56 | 3.05M |
| Oct 5, 2026 | $39.83 | $39.88 | $39.18 | $39.51 | 3.8M |
| Oct 2, 2026 | $39.58 | $40.07 | $39.50 | $39.92 | 4.34M |
Latest SNY news
The latest Smart Investors Daily articles mentioning SNY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SNY research
Overview
Company profile and research snapshot.
Company profile
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $57.02
- Implied upside
- —
- Analysts
- 14
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | ROTHSCHILD & CO REDBURN | Neutral | — |
| Sep 21, 2026 | BERENBERG | Buy | — |
| Sep 8, 2026 | LEERINK PARTNERS | Outperform | — |
| Sep 4, 2026 | ODDO BHF | Buy | — |
| Aug 31, 2026 | INTESA SANPAOLO EQUITY RESEARCH | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 20, 2026
Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk
Sanofi looks undervalued at 8.4x P/E with 5.8% yield; Dupixent-led growth and pipeline launches could drive 15%+ upsideâclick to read the SNY Buy thesis.
Yahoo · Oct 20, 2026
Investors pledge 230 billion euros at German summit: Merz
Major companies at an economic summit hosted by the German government have committed to investing around 230 billion euros ($258 billion), Chancellor Friedrich Merz said Tuesday in Berlin. The chancellor noted Amazon investments worth 16 billion euros and a German government partnership with US chipmaking giant Nvidia.
Yahoo · Oct 20, 2026
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth
GSK's newer drugs, expanding indications and promising pipeline could drive long-term growth, with sales expected to exceed 40 billion pounds by 2031.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
